Mostrar el registro sencillo del ítem
dc.contributor.author | Hernandez-Sanmiguel, Esther | |
dc.contributor.author | Gargini, Ricardo | |
dc.contributor.author | Cejalvo, Teresa | |
dc.contributor.author | Segura-Collar, Berta | |
dc.contributor.author | Nuñez-Hervada, Paula | |
dc.contributor.author | Hortigüela, Rafael | |
dc.contributor.author | Sepúlveda-Sánchez, Juan Manuel | |
dc.contributor.author | Hernández-Laín, Aurelio | |
dc.contributor.author | Pérez-Núñez, Angel | |
dc.contributor.author | Sanz, Eduardo | |
dc.contributor.author | Sánchez-Gómez, Pilar | |
dc.date.accessioned | 2020-03-02T09:54:32Z | |
dc.date.available | 2020-03-02T09:54:32Z | |
dc.date.issued | 2019 | |
dc.identifier.citation | Oxid Med Cell Longev. 2019 Aug 5;2019:9719730. | es_ES |
dc.identifier.issn | 1942-0900 | es_ES |
dc.identifier.uri | http://hdl.handle.net/20.500.12105/9163 | |
dc.description.abstract | Glioblastoma (GBM) is the most common and devastating primary brain tumor. The presence of cancer stem cells (CSCs) has been linked to their therapy resistance. Molecular and cellular components of the tumor microenvironment also play a fundamental role in the aggressiveness of these tumors. In particular, high levels of hypoxia and reactive oxygen species participate in several aspects of GBM biology. Moreover, GBM contains a large number of macrophages, which normally behave as immunosuppressive tumor-supportive cells. In fact, the presence of both, hypoxia and M2-like macrophages, correlates with malignancy and poor prognosis in gliomas. Antioxidant agents, as nutritional supplements, might have antitumor activity. Ocoxin® oral solution (OOS), in particular, has anti-inflammatory and antioxidant properties, as well as antitumor properties in several neoplasia, without known side effects. Here, we describe how OOS affects stem cell properties in certain GBMs, slowing down their tumor growth. In parallel, OOS has a direct effect on macrophage polarization in vitro and in vivo, inhibiting the protumoral features of M2 macrophages. Therefore, OOS could be a feasible candidate to be used in combination therapies during GBM treatment because it can target the highly resilient CSCs as well as their supportive immune microenvironment, without adding toxicity to conventional treatments. | es_ES |
dc.description.sponsorship | The authors would like to acknowledge Atanasio Pandiella for critical comments on the manuscript, Rosella Galli for donating GBM1, and Jacqueline Gutiérrez, Daniela Moiseev, Daniel Batzan, and Mario Alia for their technical support. RG has been funded by the Fundación Científica Asociación Española Contra el Cáncer. Research has been funded by grants from Fundación Científica Asociación Española Contra el Cáncer (18/006) to JMS; from MINECO: Acción Estratégica en Salud (AES) PI13/01258 to AHL; AES PI17/01621 to JMS; Red Temática de Investigación Cooperativa en Cancer (RTICC) RD12/0036/0027 to AHL, JMS, APN, and PSG; and MINECO-RETOS/FEDER SAF2015-65175 to PSG. | es_ES |
dc.language.iso | eng | es_ES |
dc.publisher | Hindawi | es_ES |
dc.type.hasVersion | VoR | es_ES |
dc.rights.uri | http://creativecommons.org/licenses/by/4.0/ | * |
dc.subject.mesh | Animals | es_ES |
dc.subject.mesh | Ascorbic Acid | es_ES |
dc.subject.mesh | Glioblastoma | es_ES |
dc.subject.mesh | Humans | es_ES |
dc.subject.mesh | Macrophages | es_ES |
dc.subject.mesh | Mice | es_ES |
dc.subject.mesh | Mice, Nude | es_ES |
dc.subject.mesh | Neoplastic Stem Cells | es_ES |
dc.subject.mesh | Plant Extracts | es_ES |
dc.subject.mesh | Vitamin B 12 | es_ES |
dc.subject.mesh | Vitamin B 6 | es_ES |
dc.title | Ocoxin Modulates Cancer Stem Cells and M2 Macrophage Polarization in Glioblastoma | es_ES |
dc.type | journal article | es_ES |
dc.rights.license | Atribución 4.0 Internacional | * |
dc.identifier.pubmedID | 31467641 | es_ES |
dc.format.volume | 2019 | es_ES |
dc.format.page | 9719730 | es_ES |
dc.identifier.doi | 10.1155/2019/9719730 | es_ES |
dc.contributor.funder | Asociación Española Contra el Cáncer | |
dc.contributor.funder | Red Temática de Investigación Cooperativa en Cáncer (RTICC) (España) | |
dc.contributor.funder | Ministerio de Economía y Competitividad (España) | |
dc.description.peerreviewed | Sí | es_ES |
dc.identifier.e-issn | 1942-0994 | es_ES |
dc.relation.publisherversion | https://doi.org/10.1155/2019/9719730 | es_ES |
dc.identifier.journal | Oxidative medicine and cellular longevity | es_ES |
dc.repisalud.centro | ISCIII::Unidad Funcional de Investigación de Enfermedades Crónicas (UFIEC) | es_ES |
dc.repisalud.institucion | ISCIII | es_ES |
dc.relation.projectID | info:eu-repo/grantAgreement/ES/PI18/006 | es_ES |
dc.relation.projectID | info:eu-repo/grantAgreement/ES/PI17/01621 | es_ES |
dc.relation.projectID | info:eu-repo/grantAgreement/ES/PI13/01258 | es_ES |
dc.relation.projectID | info:eu-repo/grantAgreement/ES/RD12/0036/0027 | es_ES |
dc.relation.projectID | info:eu-repo/grantAgreement/ES/2015-65175 | es_ES |
dc.rights.accessRights | open access | es_ES |